Quantcast

Latest Lexicon Pharmaceuticals Inc. Stories

2014-09-11 16:26:05

Results from Phase 2b Clinical Study in Patients with Type 2 Diabetes Provide Evidence that SGLT1 inhibition with LX4211 Provides a Clinically Meaningful Benefit THE WOODLANDS, Texas, Sept. 11, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced a publication in the online edition of the American Diabetes Association's journal, Diabetes Care, entitled, "Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium...

2014-09-04 08:29:37

THE WOODLANDS, Texas, Sept. 4, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9, 2014 at 10:35 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived...

2014-08-08 08:25:48

THE WOODLANDS, Texas, Aug. 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived...

2014-08-05 08:32:33

Conference Call and Webcast to Follow THE WOODLANDS, Texas, Aug. 5, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its second quarter 2014 financial results on Thursday, August 7, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the second...

2014-07-09 08:27:32

Trial to Evaluate Efficacy and Safety of LX4211 in Younger Population THE WOODLANDS, Texas, July 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Up to 76 individuals with T1D,...

2014-07-07 16:24:29

THE WOODLANDS, Texas, July 7, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of Eisai Inc., the United States subsidiary of Eisai Co., Ltd. Mr. Coats joins Lexicon after 18 years of senior management experience with Eisai. As president and chief executive officer at Eisai, he...

2014-06-14 12:21:12

Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through...

2014-05-30 16:25:16

THE WOODLANDS, Texas, May 30, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 9:00 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the...

2014-05-09 08:25:44

THE WOODLANDS, Texas, May 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 13, 2014 at 1:00 PM PDT (4:00 PM EDT) in Las Vegas. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An...

2014-05-08 08:31:12

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, May 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2014. "Consistent with our focus on late-stage drug development, we have made continued, excellent progress in the enrollment of patients in...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related